Aptevo Therapeutics FY 2023 GAAP EPS $(1.420) Beats $(1.720) Estimate
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics reported its FY 2023 GAAP EPS at $(1.420), surpassing the analyst consensus estimate of $(1.720) by 17.44 percent.
March 05, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo Therapeutics reported a smaller loss per share than expected for FY 2023, with GAAP EPS of $(1.420) beating the $(1.720) estimate.
Beating earnings estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. Aptevo Therapeutics' better-than-expected loss per share indicates stronger financial health than anticipated, which could attract more investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100